Influenza virus vaccine quadrivalent - Novartis

Drug Profile

Influenza virus vaccine quadrivalent - Novartis

Alternative Names: Adjuvanted quadrivalent influenza vaccine - Novartis; aQIV - Novartis

Latest Information Update: 05 Sep 2018

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Novartis
  • Developer CSL; Novartis
  • Class Influenza A virus H1N1 vaccines; Subunit vaccines
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Phase III Influenza virus infections

Most Recent Events

  • 23 Jul 2018 Seqirus completes a phase III trial in Influenza virus infections (Prevention, In the elderly) in Estonia, Poland, Czech Republic, Latvia, Lithuania, Bulgaria, Colombia, Malaysia, Philippines, Romania, Thailand and Turkey (IM) (NCT02587221)
  • 01 May 2017 Seqirus completes a phase III trial in Influenza virus infections (In infants, In children, Prevention) in Finland, Philippines and Thailand (NCT02583256)
  • 01 Sep 2016 Phase-III clinical trials in Influenza virus infections (In the elderly, Prevention) in Czech Republic (IM)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top